S. Trojan

PFKFB3 and PFKFB4 inhibition modulates the response of metabolically plastic resistant melanoma cells to BRAF/MEK-targeted therapy

Despite the development of selective inhibitors targeting oncogenic BRAF mutations, melanoma therapy remains limited by acquired resistance driven by multiple mechanisms, including metabolic reprogramming. PFKFB isoenzymes regulate cellular adaptation to therapeutic stress and may therefore represent promising th...